Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:21:40.321Z.
Calculation as of: 2026-10-06T14:21:40.321Z.
Quote observation: 2026-10-06T14:19:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 36850a73a8dd64042e14cdb756c8aff586d88f9314e30134a37dd84cc424cdb4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$4.52M
Price/OCF Ratio
N/A
TTM Avg
35.59
3Y Avg
35.59
5Y Avg
35.59
Market Cap
$4.96M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | $4.23M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.52M | N/A | 35.59 | 35.59 | 35.59 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.29M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.20M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.06M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.72M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.73M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.96M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.57M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
